Shares of life sciences firm Invion (ASX:IVX) experienced an intraday surge of as much as 25% to reach A$0.005.

This was the company’s most significant intraday percentage gain since January 20.

The hike in stock value was spurred by an announcement that Invion signed a collaboration with South Korean firm Dr.inB.

This partnership aims to further the innovation and use of PhotosoftTM technology.

This advancement is intended to treat the human papilloma virus (HPV), a culprit of body warts.

The said PhotosoftTM technology employs non-toxic photosensitisers and visible light in synergy to treat a range of medical conditions spanning various cancers, atherosclerosis, and infectious diseases.

On the day of the announcement, roughly 1.7 million shares were traded, exceeding the 30-day average volume by 2.5 times.

Notwithstanding the surge in share value, the company’s stock was still down by 20% for the year to date.

Invion is a life sciences company that partners with like-minded firms to develop beneficial medical technology.